Exelixis Inc
EXEL40.880USD
-0.510-1.23%
Handelsschluss 12/12, 16:00（ET）Kurse um 15 Minuten verzögert
10.96BMarktkapitalisierung
16.62KGV TTM
mehr Informationen über Exelixis Inc Unternehmen
Exelixis, Inc. is an oncology company. The Company has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. It is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.
Exelixis Inc Informationen
BörsenkürzelEXEL
Name des UnternehmensExelixis Inc
IPO-datumApr 11, 2000
CEOMorrissey (Michael M)
Anzahl der mitarbeiter1147
WertpapierartOrdinary Share
GeschäftsjahresendeApr 11
Addresse1851 Harbor Bay Parkway
StadtALAMEDA
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl94502
Telefon16508377000
Websitehttps://www.exelixis.com/
BörsenkürzelEXEL
IPO-datumApr 11, 2000
CEOMorrissey (Michael M)
Führungskräfte von Exelixis Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Michael M. Morrissey, Ph.D.
Dr. Michael M. Morrissey, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.17M
-4.48%
Dr. Stelios B. Papadopoulos, Ph.D.
Dr. Stelios B. Papadopoulos, Ph.D.
Independent Chairman of the Board, Co-Founder
Independent Chairman of the Board, Co-Founder
1.17M
-7.87%
Mr. Jeffrey J. Hessekiel, J.D.
Mr. Jeffrey J. Hessekiel, J.D.
Executive Vice President
Executive Vice President
410.70K
-12.57%
Dr. Dana T. Aftab, Ph.D.
Dr. Dana T. Aftab, Ph.D.
Executive Vice President - Research and Development
Executive Vice President - Research and Development
359.32K
-8.22%
Mr. Jack L. Wyszomierski
Mr. Jack L. Wyszomierski
Independent Director
Independent Director
340.04K
-2.17%
Mr. Patrick Joseph Haley
Mr. Patrick Joseph Haley
Executive Vice President - Commercial
Executive Vice President - Commercial
220.48K
-14.72%
Dr. George H. Poste, Ph.D.
Dr. George H. Poste, Ph.D.
Independent Director
Independent Director
159.99K
+6.53%
Dr. Brenda Hefti, J.D., Ph.D.
Dr. Brenda Hefti, J.D., Ph.D.
General Counsel
General Counsel
120.61K
+33.36%
Dr. Maria C. Freire, Ph.D.
Dr. Maria C. Freire, Ph.D.
Independent Director
Independent Director
81.98K
+13.60%
Ms. Julie Anne Smith
Ms. Julie Anne Smith
Independent Director
Independent Director
10.57K
+1285.98%
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Michael M. Morrissey, Ph.D.
Dr. Michael M. Morrissey, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.17M
-4.48%
Dr. Stelios B. Papadopoulos, Ph.D.
Dr. Stelios B. Papadopoulos, Ph.D.
Independent Chairman of the Board, Co-Founder
Independent Chairman of the Board, Co-Founder
1.17M
-7.87%
Mr. Jeffrey J. Hessekiel, J.D.
Mr. Jeffrey J. Hessekiel, J.D.
Executive Vice President
Executive Vice President
410.70K
-12.57%
Dr. Dana T. Aftab, Ph.D.
Dr. Dana T. Aftab, Ph.D.
Executive Vice President - Research and Development
Executive Vice President - Research and Development
359.32K
-8.22%
Mr. Jack L. Wyszomierski
Mr. Jack L. Wyszomierski
Independent Director
Independent Director
340.04K
-2.17%
Mr. Patrick Joseph Haley
Mr. Patrick Joseph Haley
Executive Vice President - Commercial
Executive Vice President - Commercial
220.48K
-14.72%
Umsatzaufteilung
Währung: USDAktualisiert: Mon, Oct 6
Währung: USDAktualisiert: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
CABOMETYX
517.89M
91.14%
License revenues
49.30M
8.68%
COMETRIQ
2.12M
0.37%
Collaboration services revenues
-1.05M
-0.19%
Nach RegionUSD
Name
Umsatz
Anteil
U.S
524.77M
92.35%
Europe
37.03M
6.52%
Japan
6.46M
1.14%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
CABOMETYX
517.89M
91.14%
License revenues
49.30M
8.68%
COMETRIQ
2.12M
0.37%
Collaboration services revenues
-1.05M
-0.19%
Aktionärsstatistik
Aktualisiert: Fri, Nov 21
Aktualisiert: Fri, Nov 21
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
The Vanguard Group, Inc.
9.70%
BlackRock Institutional Trust Company, N.A.
9.33%
Farallon Capital Management, L.L.C.
7.27%
Renaissance Technologies LLC
5.77%
State Street Investment Management (US)
4.15%
Andere
63.79%
Aktionäre
Aktionäre
Anteil
The Vanguard Group, Inc.
9.70%
BlackRock Institutional Trust Company, N.A.
9.33%
Farallon Capital Management, L.L.C.
7.27%
Renaissance Technologies LLC
5.77%
State Street Investment Management (US)
4.15%
Andere
63.79%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
43.96%
Investment Advisor/Hedge Fund
30.84%
Hedge Fund
15.65%
Pension Fund
3.02%
Individual Investor
2.18%
Research Firm
2.01%
Sovereign Wealth Fund
1.26%
Bank and Trust
0.61%
Family Office
0.19%
Andere
0.28%
Institutionelle Beteiligung
Aktualisiert: Mon, Dec 8
Aktualisiert: Mon, Dec 8
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
1065
260.68M
98.50%
--
2025Q3
1092
260.70M
99.86%
-131.97K
2025Q2
1104
260.91M
98.66%
+4.64M
2025Q1
1034
261.04M
99.05%
-11.93M
2024Q4
973
257.78M
94.19%
+2.55M
2024Q3
898
254.99M
92.51%
+5.22M
2024Q2
882
250.15M
93.36%
-9.07M
2024Q1
880
259.43M
91.82%
-18.97M
2023Q4
863
265.17M
90.49%
-5.75M
2023Q3
825
271.59M
91.03%
-8.20M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
The Vanguard Group, Inc.
27.41M
10.18%
-1.20M
-4.20%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
25.44M
9.45%
-1.05M
-3.97%
Jun 30, 2025
Farallon Capital Management, L.L.C.
16.04M
5.96%
-2.60M
-13.95%
Jun 30, 2025
Renaissance Technologies LLC
15.82M
5.88%
+995.50K
+6.72%
Jun 30, 2025
State Street Investment Management (US)
11.38M
4.23%
-404.95K
-3.43%
Jun 30, 2025
AQR Capital Management, LLC
7.61M
2.83%
+712.19K
+10.33%
Jun 30, 2025
Fuller & Thaler Asset Management Inc.
8.78M
3.26%
+980.50K
+12.58%
Jun 30, 2025
LSV Asset Management
7.82M
2.9%
-340.89K
-4.18%
Jun 30, 2025
Geode Capital Management, L.L.C.
7.45M
2.77%
+28.29K
+0.38%
Jun 30, 2025
Arrowstreet Capital, Limited Partnership
5.26M
1.95%
+1.58M
+42.93%
Jun 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
First Trust NYSE Arca Biotechnology Index Fund
3.41%
iShares Genomics Immunology and Healthcare ETF
3.38%
Tema Oncology ETF
3.13%
ERShares Entrepreneurs ETF
2.68%
Invesco Biotechnology & Genome ETF
2.68%
AAM Sawgrass US Large Cap Quality Growth ETF
2.59%
Alger Russell Innovation ETF
2.12%
State Street SPDR S&P Biotech ETF
2.02%
Inspire Growth ETF
1.92%
Invesco S&P MidCap Quality ETF
1.89%
Mehr Anzeigen
First Trust NYSE Arca Biotechnology Index Fund
Anteil3.41%
iShares Genomics Immunology and Healthcare ETF
Anteil3.38%
Tema Oncology ETF
Anteil3.13%
ERShares Entrepreneurs ETF
Anteil2.68%
Invesco Biotechnology & Genome ETF
Anteil2.68%
AAM Sawgrass US Large Cap Quality Growth ETF
Anteil2.59%
Alger Russell Innovation ETF
Anteil2.12%
State Street SPDR S&P Biotech ETF
Anteil2.02%
Inspire Growth ETF
Anteil1.92%
Invesco S&P MidCap Quality ETF
Anteil1.89%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Exelixis Inc?
Die fünf größten Anteilseigner von Exelixis Inc sind:
The Vanguard Group, Inc. hält 27.41M Aktien, was 10.18% der Gesamtaktien entspricht.
BlackRock Institutional Trust Company, N.A. hält 25.44M Aktien, was 9.45% der Gesamtaktien entspricht.
Farallon Capital Management, L.L.C. hält 16.04M Aktien, was 5.96% der Gesamtaktien entspricht.
Renaissance Technologies LLC hält 15.82M Aktien, was 5.88% der Gesamtaktien entspricht.
State Street Investment Management (US) hält 11.38M Aktien, was 4.23% der Gesamtaktien entspricht.
The Vanguard Group, Inc. hält 27.41M Aktien, was 10.18% der Gesamtaktien entspricht.
BlackRock Institutional Trust Company, N.A. hält 25.44M Aktien, was 9.45% der Gesamtaktien entspricht.
Farallon Capital Management, L.L.C. hält 16.04M Aktien, was 5.96% der Gesamtaktien entspricht.
Renaissance Technologies LLC hält 15.82M Aktien, was 5.88% der Gesamtaktien entspricht.
State Street Investment Management (US) hält 11.38M Aktien, was 4.23% der Gesamtaktien entspricht.
Was sind die drei wichtigsten Anteilseigner-Typen von Exelixis Inc?
Die drei wichtigsten Anteilseigner-Typen von Exelixis Inc sind:
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
Farallon Capital Management, L.L.C.
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
Farallon Capital Management, L.L.C.
Wie viele Institutionen halten Anteile an Exelixis Inc (EXEL)?
Mit Stand vom 2025Q4 halten 1065 Institutionen Anteile an Exelixis Inc, mit einem Gesamtmarktwert von etwa 260.68M, was 98.50% der Gesamtanteile entspricht. Im Vergleich zum 2025Q3 ist der institutionelle Aktienbesitz um -1.36% gestiegen.
Was ist die größte Einnahmequelle von Exelixis Inc?
Am FY2025Q2 erzielte das Geschäft mit CABOMETYX für Exelixis Inc den höchsten Umsatz in Höhe von 517.89M, was 91.14% des Gesamtumsatzes entspricht.
